Ascendiant Capital Rates Aytu BioPharma (AYTU) buy

Ascendiant Capital maintains its buy rating on Aytu BioPharma with a $14.5 price target, as the stock is currently at $2.19, a 561.32% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ascendiant Capital rated Aytu BioPharma, Inc. ($AYTU) "buy" with a $14.50 price target on June 11, 2026.

Since the rating, $AYTU is up 5.5% after 1 week, down 0.5% after 1 month and down 6.8% to date (from the $2.19 close on Jun 11, 2026).

AYTU Aytu BioPharma, Inc.

$2.04 -26.35% year to date

Daily close · Oct 16, 2026

Key Points

Ascendiant Capital reiterated its buy rating on Aytu BioPharma, with a price target of $14.5, up from a previous target of $14.5.
Ascendiant Capital's $14.50 price target implies 561.32% upside from Aytu BioPharma, Inc.'s ($AYTU) current $2.19 share price.
Aytu BioPharma's shares are currently trading at $2.19, significantly below the target price.
This rating comes as Aytu BioPharma continues to operate in the specialty pharmaceuticals sector, focusing on ADHD treatments.

Get $AYTU trade alerts by text

We text you when insiders, Congress or big funds trade $AYTU. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Aytu BioPharma, Inc. alert may contain errors. Disclosures

Ascendiant Capital's Rating on AYTU

On June 11, 2026, Ascendiant Capital reiterated its buy rating on Aytu BioPharma, Inc. (AYTU) with a price target of $14.5 while the stock is currently trading at $2.19. This action follows their previous target of $14.5, indicating their continued confidence in the company's potential despite the low share price.

How This Rating Stacks Up

Ascendiant Capital’s maintained buy rating aligns with its recent evaluations of other companies. Just a day earlier, on June 10, 2026, the firm reiterated a buy rating for Synergy CHC Corp. with a target of $3.75. This trend of confidence reflects Ascendiant's overall positive stance toward several stocks in the healthcare sector, showing a consistent approach in their evaluations.

Stock Performance Context

Aytu BioPharma's shares are trading at $2.19, slightly up from the previous close of $2.12. The stock has fluctuated between a 52-week low of $1.65 and a high of $3.07, highlighting potential volatility. The current price is well below the $14.5 target set by Ascendiant Capital, suggesting a significant upside potential if the company's performance improves.

12-month forecast

$AYTU price target

Aytu BioPharma, Inc. daily closes and this analyst's $14.50 target. Not advice.

What AYTU Does

Aytu BioPharma, Inc. develops and markets novel therapeutics, focusing on treatments for attention deficit hyperactivity disorder (ADHD) among other prescription products. The company is based in Denver, Colorado, and operates in the healthcare sector, which remains competitive.

What to Watch at AYTU

Investors should keep an eye on Aytu BioPharma's next earnings report, scheduled for May 14, 2025. As the firm continues to file periodic updates, the reiteration of the buy rating by Ascendiant Capital reflects a backward-looking perspective, which may not capture current market dynamics.